---
title: FidoCure blog | Dr. Lucas Rodrigues
description: Read the latest in veterinary oncology research and FidoCure® scientific and clinical updates.
---
[](https://www.fidocure.com/)
- [Veterinarians](https://fidocure.com/for-veterinarians/)
- [Portal Login](https://dvm.fidocure.com/)
- [Veterinary Blog](https://blog.fidocure.com/fidocure-blog/tag/vet)
- [Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies)
- [Webinars](https://blog.fidocure.com/fidocure-blog/tag/webinars)
- [Pet Parents](https://fidocure.com/pet-parents/)
- [About Us](https://fidocure.com/about-us/)
- [How it works](https://fidocure.com/how-it-works/)
- [Find a Clinic](https://fidocure.com/find-a-clinic/)
- [Contact Us](https://fidocure.com/contact-us/)
# FidoCure Veterinary Team Blog
### Read the latest in veterinary oncology research and FidoCure scientific and clinical updates from our team of experts and advisors
Select Category Case Studies Press Vet Webinars
This is a search field with an auto-suggest feature attached.
- There are no suggestions because the search field is empty.
Posts by:
## Dr. Lucas Rodrigues
### [Why Genetic Testing Matters Before Using Targeted Small Molecule Therapies in Cancer Treatment](https://blog.fidocure.com/fidocure-blog/why-genetic-testing-matters-before-using-targeted-small-molecule-therapies-in-cancer-treatment)
*Lucas Rodrigues, DVM, MS, PhD
Head of Veterinary Research at FidoCure*
Precision medicine has revolutionized human oncology by enabling treatments tailored to the unique genetic makeup of each tumor. Now, this same approach is being increasingly adopted in veterinary medicine, bringing a new level of sophistication to cancer care in dogs. Small molecule targeted therapies are at the forefront of this movement, offering the potential for more effective and individualized treatments. However, **their success depends on a critical first step: identifying the genetic drivers behind each tumor**. Without this information, the use of targeted therapies becomes a gamble, especially risky in aggressive cancers with diverse genetic profiles, where delays in effective treatment can have serious consequences.
[Read More](https://blog.fidocure.com/fidocure-blog/why-genetic-testing-matters-before-using-targeted-small-molecule-therapies-in-cancer-treatment)
### [Innovative Bioinformatics Pipeline Reduces Costs and Expands Access to Precision Therapeutics for Canine Oncology](https://blog.fidocure.com/fidocure-blog/innovative-bioinformatics-pipeline-reduces-costs-and-expands-access-to-precision-therapeutics-for-canine-oncology)
Today we would like to share another exciting development in the field of canine oncology genetics and precision therapeutics from our manuscript ["Shared Hotspot Mutations in Oncogenes Position Dogs as an Unparalleled Comparative Model for Precision Therapeutics,](https://www.nature.com/articles/s41598-023-37505-2?fbclid=IwAR0dZ8PUQB3BmX-8OeySAKt-1aMPmHqPeJId93WhmpeweMEKGq0XkBwRLw4)" recently published in[Scientific Reports](https://www.nature.com/articles/s41598-023-37505-2?fbclid=IwAR0dZ8PUQB3BmX-8OeySAKt-1aMPmHqPeJId93WhmpeweMEKGq0XkBwRLw4).
[Read More](https://blog.fidocure.com/fidocure-blog/innovative-bioinformatics-pipeline-reduces-costs-and-expands-access-to-precision-therapeutics-for-canine-oncology)
.png)
### [Canine Cancer Osteosarcoma Research](https://blog.fidocure.com/fidocure-blog/canine-cancer-osteosarcoma-research)
In our relentless pursuit of advancements in veterinary oncology, the FidoCure Team's research has taken center stage, offering an in-depth exploration into the realm of canine osteosarcoma. The use of real-world data and machine learning techniques promises to provide invaluable insights into the mutation patterns and treatment outcomes associated with this challenging condition.
[Read More](https://blog.fidocure.com/fidocure-blog/canine-cancer-osteosarcoma-research)
### [Mammary Carcinoma: Insights from BRCA1 mutations](https://blog.fidocure.com/fidocure-blog/mammary-carcinoma-insights-from-brca1-mutations)
**Genetic Signatures in Canine Mammary Tumors: insights from *BRCA1* mutations**
[Read More](https://blog.fidocure.com/fidocure-blog/mammary-carcinoma-insights-from-brca1-mutations)
.png)
### [Cancer Does Not Have to Be a Death Sentence](https://blog.fidocure.com/fidocure-blog/cancer-does-not-have-to-be-a-death-sentence)
[Read More](https://blog.fidocure.com/fidocure-blog/cancer-does-not-have-to-be-a-death-sentence)
### [FidoCure® Precision Medicine Data Showcased at the American Association of Cancer Research (AACR)](https://blog.fidocure.com/fidocure-blog/new-comparative-oncology-research-showcasing-power-of-real-world-data-from-dogs-with-cancer)
At the [AACR 2023 annual meeting](https://www.aacr.org/), Dr. Lucas Rodrigues, Head of Veterinary Research at FidoCure®, presented the results of two innovative studies which demonstrated the power of real-world data from dogs with cancer to drive drug development strategies and inform human clinical trials.
The first study, titled "High frequency of TP53 mutations in canine skin tumors recapitulates solar induced human lesions representing an important research model of spontaneous diseases," focused on the similarities between skin tumors in dogs and humans caused by sun exposure. The study found a high frequency of TP53 mutations in canine skin tumors, mirroring those seen in humans with solar-induced skin lesions. This validates the use of dogs as a valuable research model for spontaneous diseases.
[Read More](https://blog.fidocure.com/fidocure-blog/new-comparative-oncology-research-showcasing-power-of-real-world-data-from-dogs-with-cancer)
- [How it Works](https://fidocure.com/how-it-works/)
- [FAQ](https://fidocure.com/faq/)
- [Contact Us](https://fidocurestg.wpengine.com/contact-us/)
- [For Vets](https://fidocure.com/for-veterinarians/)
- [About Us](https://fidocure.com/about-us/)
- [Terms of Service](https://fidocure.com/terms-of-service/)
- [Blog](https://blog.fidocure.com/fidocure-blog)
- [Careers](https://fidocure.com/careers/)
- [Privacy Policy](https://fidocure.com/privacy-policy/)
-
-
-
-
**FidoCure® is an advanced cancer-care service for dogs, developed by One Health Company**. DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy.
© Copyright 2018-2026 One Health Company, All rights reserved